- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04945876
Exercise Adherence and Optimal Nutrition Post Rehabilitation Among People With Parkinson's Disease (mHEXANUT)
Effect of Mobile Health Technology (mHealth), Exercise Adherence and Optimal Nutrition Post Rehabilitation Among People With Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is found that regular, structured exercise is especially important for people with Pakinson disease (PD) and it is a key element in the treatment of PD at rehabilitation centers in Norway. A substantial amount of research indicate that exercise can lead to improvements in physical functioning, strength, balance, gait, and HRQOL among people with PD. However, after a supervised exercise period, these measures tend to return toward baseline values. This regression may to some extent reflect the progressive nature of PD, but previous research suggests that maintaining the motivation to stay physically active is difficult once formalized interventions end. Furthermore, research indicate that nutritional status is an important predictor for health status among people with PD and that PD patients have high rates of unintentional weight loss compared to age-matched controls. In other words, research indicate that follow-up at home after rehabilitation is necessary to increase optimal nutrition and continuing to exercise.
This is a randomized controlled trial meant to evaluate the effect of six months digital follow-up, after a 3-5 week stay at a inpatient rehabilitation center, on functional and nutritional status in people with PD.
Eligible participants will be recruited from Unicare Fram Rehabilitation center by a physical therapist and research assistant in collaboration with Unicare Fram employees and a Ph.D student. Informed consent from the participants is obtained from persons with no previous relationship to the patients, and who are not included in their daily treatment, mainly the research assistant. After baseline testing the participants will be randomly allocated to an intervention- or control group.
The intervention in this study is designed to increase the level of adherence after rehabilitation by implementing factors that previous studies have proven successful such as education, goal setting, follow-up from health care personnel and use of mHealth Technology. The intervention consist of 2 phases.
Phase 1: All participants will receive the rehabilitation program currently provided at Unicare Fram rehabilitation center. This is a comprehensive and interdisciplinary rehabilitation program with focus on self-management of the disease including exercise and nutrition.
Phase 2: The control group will receive no further follow-up. The intervention group will receive digital follow up once a month focusing on goals and motivation, and an activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and intensity control.
All participants will be retested after 12 weeks and 6 months at Unicare Fram rehabilitation center by the research assistant.
Descriptive data will be reported for variables of interest. The data will be analyzed following the intention to treat principle. Prospective differences in primary and secondary outcomes and baseline characteristics between the intervention group and the control group will be assessed by t-tests for continuous and normal distributed variables and with non-parametric tests for categorical variables. Multiple linear and logistic regression modelling will be used to control for confounding of between-group differences. The latest version of Statistical Package of the Social Sciences (SPSS) will be used.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sigrid R Alnes, MSc
- Phone Number: +4747648388
- Email: sigridry@oslomet.no
Study Contact Backup
- Name: Therese Brovold, Ph.D
- Phone Number: 47238558
- Email: therbrov@oslomet.no
Study Locations
-
-
Bærum
-
Rykkin, Bærum, Norway, 1349
- Recruiting
- Unicare Fram Rykkin
-
Contact:
- Annette F Vistven
- Phone Number: 92461400
- Email: annettev@oslomet.no
-
Contact:
- Helene Haakand
- Phone Number: 48028311
- Email: helene.haaland@unicare.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- >40 years
- Living at home
- Living max 2,5 hours travel distance from Unicare Fram
- A diagnosis of idipathic PD
- Hoehn-Yahr stage 1-3
- eternal feeding ability
- must own a smart phone
Exclusion Criteria:
- Hoehn-Yahr stage 4-5
- Medical issues that might affect participation in exercise programs
- Diagnosis of dementia
- Diagnosis of severe dysphagia
- Exercises regularly more than twice a week(structured exercise).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control group
Participants is encouraged to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center. No further follow up except for testing at 12 weeks and six months. After the completion of the study the control group will be offered a session of individual exercise and diet guidance as well as a period of digital follow-up as needed. |
|
EXPERIMENTAL: Intervention group
Participants will receive a session of individual exercise and diet guidance with focus on goals and motivation for diet and exercise and help to overcome any barriers for self-efficacy.
They will also receive an activity tracker and an introduction on how to use it.
Further they will receive a monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise.
The participants can also send sms if they have questions during the follow-up period.
They will be encouraged to continue to follow the home-based rehabilitation plan based on the recommendations from the rehabilitation center.
If needed they can get help to find suitable exercise groups in their own municipality.
The Garmin wristband will be used to facilitate daily activity and continuing exercise at recommended intensity level at home.
Participants who are malnourished, or at risk of malnutrition, will receive specific guidance session on nutrition.
|
Participants will receive: One session of individual exercise and diet guidance focusing on goals and motivation. An activity tracker and instructions on how to use it both for motivation, daily activity tracking, logging of specific exercise and using the wristbands heart rate monitor to control intensity level during exercise. Monthly digital follow-up to provide support and address questions and goals regarding nutrition, daily energy expenditure and exercise. Opportunity to send sms with questions regarding nutrition and exercise. Participants who are malnourished, or at risk of malnutrition will be offered a total of two hours of additional individualized, digital guidance on nutrition as needed. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six minute walk test (6MWT)
Time Frame: measured at baseline, 12 weeks and 6 months
|
A sub-maximal exercise test used to assess aerobic capacity and endurance.
The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
It evaluates the functional capacity of the individual.
|
measured at baseline, 12 weeks and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Parkinson's disease questionnaire (PDQ-39)
Time Frame: measured at baseline, 12 weeks and 6 months
|
A 39 item, patient reported measure of health status and quality of life over the last month.
It assesses how often people affected by parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
The answers results in a score from 0-100 points in each dimension.
Lower scores reflect better QoL.
|
measured at baseline, 12 weeks and 6 months
|
The Patients-Generated subjective Global Assessment Short Form (PG-SGA)
Time Frame: measured at baseline, 12 weeks and 6 months
|
It is a component of a nutritional assessment tool wich could be used for descriptive nutrition screening.
A 4 item questionnaire assessing weight, food-intake, symptoms affecting food intake and activity & function.
The answers result in a score from 0-9, 0 indicates no need for nutritional measures, 9 indicates a critical need for nutritional measures.
|
measured at baseline, 12 weeks and 6 months
|
mini best test
Time Frame: measured at baseline, 12 weeks and 6 months
|
The test is used to identify risk of falling, changes in balance over time and distinguish between different balance challenges.
|
measured at baseline, 12 weeks and 6 months
|
and 5x sit-to-stand
Time Frame: measured at baseline, 12 weeks and 6 months
|
Assesses functional lower extremity strength, transitional movements, balance and fall risk
|
measured at baseline, 12 weeks and 6 months
|
Bioelectrical impedance analysis
Time Frame: measured at baseline, 12 weeks and 6 months
|
A method for estimating body composition, in particular body fat and muscle mass.
|
measured at baseline, 12 weeks and 6 months
|
What do you eat
Time Frame: measured at baseline
|
A food frequency questionnaire used to assess the diet of a population during the last seven days.
Contains questions on how often and how much you eat of specific food groups.
The questionnaire does not result in a score.
it can be used to raise awareness and to assess on what areas potential nutritional measures is needed.
|
measured at baseline
|
Radboud Oral Motor Inventory for Parkinson's disease (ROMP) - swallowing
Time Frame: measured at baseline, 12 weeks and 6 months
|
A self-report questionnaire with 7 questions assessing potential swallowing difficulties.
The answers results in a score from 7-35 point.
A low score indicates little to no problems with swallowing, i high score indicates a higher degree of problems with swallowing.
|
measured at baseline, 12 weeks and 6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201660 mHEXANUT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Digital follow-up
-
Turku University HospitalUniversity of Turku; University of HelsinkiRecruitingPreterm Birth | Growth Disorders | Sensory Disorder | Family Relations | Development DelayFinland
-
Istanbul University - Cerrahpasa (IUC)CompletedInfertility | Psychological Distress | Infertility, Female | Depression, Anxiety | Nurse's RoleTurkey
-
M.D. Anderson Cancer CenterRecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Connolly Hospital BlanchardstownCompletedGeneral Surgery | Outpatients | Virtual Clinic | Text MessagingIreland
-
Sport Injury Prevention Research CentreGeneral Electric; National Basketball AssociationCompletedTendinopathy | Sports Injuries in Children | Injury, Knee | Injury, AnkleCanada
-
Centre Hospitalier Universitaire, AmiensRecruitingQuality of Life | Pain | Lumbar Spine SurgeryFrance
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Trialbureau... and other collaboratorsRecruitingAdolescent Idiopathic ScoliosisNetherlands
-
Rennes University HospitalUnknown
-
University of IcelandMemorial Sloan Kettering Cancer Center; Landspitali University Hospital; deCODE... and other collaboratorsActive, not recruitingMonoclonal Gammopathy of Undetermined SignificanceIceland